MedPath

Zona Pellucida Bound Sperm vs. Embryologist Selected Sperm for Intracytoplasmic Sperm Injection

Not Applicable
Recruiting
Conditions
Infertility
Interventions
Other: Zona Pellucida-Bound Sperm Selection for ICSI
Other: Routine Embryologist Selected Sperm
Registration Number
NCT05859152
Lead Sponsor
IVI America
Brief Summary

This study aims to assess the clinical significance of the intracytoplasmic sperm injection (ICSI) with zona-pellucida (ZP) bound sperm compared to ICSI with embryologist selected sperm for patients undergoing in vitro fertilization treatment of their infertility.

Detailed Description

In this study, the investigators aim to determine the clinical utility of the ZP-bound sperm selection methodology for ICSI. This study will be a prospective, split cohort, randomized, control trial comparing the routine standard of sperm selection for ICSI via the embryologist versus sperm selected via ZP-binding for ICSI. Embryology, ploidy and clinical pregnancy outcomes will be assessed.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Undergoing their first in vitro fertilization (IVF) cycle
  • Electing single embryo transfer
  • Electing preimplantation genetic testing for aneuploidy (PGT-A) of their embryos
  • Female partners age <42 years old at start of vaginal oocyte retrieval cycle, but >18 years old.
  • Normal ovarian reserve:
  • Antimullerian hormone level (AMH) ≥ 1.2 ng/mL
  • Antral follicle count (AFC) ≥ 8
  • At least 4 mature oocytes (M2s) retrieved at the VOR procedure in order to randomize
  • At least 1 immature oocyteretrieved at the VOR procedure to perform ZP binding co-incubation procedure
  • Intention to transfer the morphological best quality, euploid, embryo at the frozen embryo transfer procedure
Exclusion Criteria
  • Contraindication to IVF
  • Clinical indication for preimplantation genetic testing (i.e., screening for single gene disorder, chromosomal translocation, or any other disorders requiring a more detailed embryo genetic analysis)
  • Male partner with azoospermia or oligozoospermia (<100,000 total motile spermatozoa)
  • Male partner with Y-chromosome microdeletion
  • Male partner with any Karyotype other than 46,XY
  • Male partner requiring surgically obtained sperm either via testicular or epididymal retrieval procedures
  • Uncorrected hydrosalpinges that communicate with the endometrial cavity
  • Endometrial Insufficiency, as defined by a prior cycle with maximal endometrial thickness <6mm,), or persistent endometrial fluid
  • Donor oocyte cycles
  • Gestational carriers

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ZP Bound Sperm Selection Oocyte CohortZona Pellucida-Bound Sperm Selection for ICSIThis is half of the patient's mature oocytes that will be inseminated via the ICSI procedure with sperm that has bound to the ZP of an immature oocyte.
Routine Care: Embryologist Selected Sperm Oocyte CohortRoutine Embryologist Selected SpermThis is half of the patient's mature oocytes that will be inseminated via the ICSI procedure per routine with sperm that is subjectively selected by the embryologist (based on morphology and mobility characteristics). This is the current standard of care for ICSI.
Primary Outcome Measures
NameTimeMethod
Blastulation Rateone week after the vaginal oocyte retrieval and ICSI procedure

Blastulation rates per mature oocyte of ZP-bound versus embryologist selected sperm after ICSI.

Secondary Outcome Measures
NameTimeMethod
Fertilization Rate24 hours post ICSI procedure

fertilization rates per mature oocyte of ZP-bound versus embryologist selected sperm after ICSI.

Blastocyst Ploidy RateApproximately 2 weeks after trophectoderm biopsy

Preimplantation genetic testing for aneuploidy will be performed at the blastocyst stage and ploidy status compared between groups

Sustained Implantation RatesApproximately 6 weeks after frozen embryo transfer procedure

The number of participants discharged at 8-9 weeks gestational age to their obstetrician.

Trial Locations

Locations (1)

Reproductive Medicine Associates of Northern California

🇺🇸

San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath